Apollomics logo

Apollomics(NASDAQ) APLMW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-98%
5 YearN/A
1 Year-47%
1 Month-27%
$0.01
-3.81%
-0.00Today
Apollomics last closing stock price
MetricPriceDate
Last closeUSD 0.012026-10-07
Apollomics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.84%USD 0.012026-09-30
1 month-26.81%USD 0.012026-09-04
3 month-29.86%USD 0.012026-07-09
Year to date-9.01%USD 0.012025-12-31
1 year-47.12%USD 0.022025-09-17
3 year-79.8%USD 0.052023-10-05
Since inception-97.85%USD 0.472021-11-26

Apollomics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$8.70M

Net Income (TTM)

-$64.80M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.02 (Low)

Price

$0.01

Volume

531

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $0.23

Estimated Earnings Date

Sep 24, 2026

APLMW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Apollomics

Apollomics, Inc. is a clinical-phase biotechnology company focused on developing innovative cancer treatments to address significant unmet patient needs. Founded in 2015 and based in Foster City, California, the company aims to advance its pipeline of therapies through rigorous research and development.

Products and Services
  • Novel cancer therapies targeting various malignancies
  • Clinical trials to evaluate the efficacy and safety of treatments
  • Collaborations with research institutions for drug development
Growth Outlook
  • Recent quarterly revenue reached $8.5 million, indicating market interest
  • Strong focus on R&D with $9.11 million spent in the latest quarter
  • Potential for future partnerships to enhance product pipeline
Financial Highlights
  • Trailing twelve months (TTM) revenue of $8.5 million
  • Net income for the latest quarter was $1.6 million
  • Cash and cash equivalents totaled $3.28 million as of the last quarter
Apollomics, Inc. operates in the dynamic biotechnology sector, where innovation is crucial for success. The company's commitment to developing novel cancer therapies positions it well within a growing market. The recent revenue figures reflect a positive trajectory, suggesting that the company is gaining traction in its efforts to meet the needs of patients with cancer. The significant investment in research and development underscores the focus on advancing its product pipeline, which may lead to future growth opportunities. With a solid cash position, Apollomics is poised to navigate the challenges of the biotechnology landscape while striving to deliver impactful treatments.
AI Generated • Sep 20, 2026

Industry

Biotechnology

Headquarters

Foster City, CA 94404, US

APLMW Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-111.45%

Net Income Margin

-128.69%

Return on Equity

288.40%

Return on Capital

N/A

Return on Assets

-162.93%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

531

Avg. Volume

19.53K

Financials (TTM)

Gross Profit

$8.70M

Operating Income

-$51.61M

EBITDA

-$50.13M

Operating Cash Flow

-$57.92M

Capital Expenditure

-$24.00K

Free Cash Flow

-$57.95M

Cash & ST Invst.

$3.28M

Total Debt

$643.00K

Apollomics Performance Analysis

Apollomics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30430.9%
Q42024-12-31-188.8%
Q22025-06-30641.4%
Q42025-12-31-100.0%
Apollomics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-15733.3%
Q42024-12-3155.5%
Q22025-06-3032.8%
Q42025-12-31133.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

14

N/A

Net Income

$1.60M

+107.3%

EBITDA

$3.14M

+111.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$3.28M

-91.3%

Total Debt

$643.00K

-86.2%

Accounts Receivable

$2.49M

+434.3%

Inventory

$0.00

N/A

Long Term Debt

$434.00K

+62.5%

Short Term Debt

$209.00K

-95.2%

Return on Assets

-1.63%

N/A

Return on Invested Capital

-24.41%

N/A

Free Cash Flow

-$10.37M

+57.5%

Operating Cash Flow

-$10.37M

+57.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KCPCKey Capital Corporation
$0.00+0.00%
PGIEPGI Energy, Inc.
$0.00+0.00%
PLMKPlum Acquisition Corp. IV
$10.63+0.00%
FGMCFG Merger II Corp.
$8.30+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$50.97-5.55%
CRWVCoreWeave
$65.12-16.32%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$41.84+11.81%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$112.65-11.70%

Questions About APLMW

What is the current price of Apollomics?

Apollomics is trading at $0.01 per share.

What is the 52-week range for Apollomics?

Over the past 52 weeks, Apollomics has traded between $0.01 and $0.23.

How much debt does Apollomics have?

Apollomics total debt is unavailable.

How much cash does Apollomics have on hand?

Apollomics does not have cash on hand data available.

What is Apollomics’s dividend yield?

Apollomics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.